MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction. (25th December 2012)

• Record Type: Journal Article
• Authors: Mhawech-Fauceglia, Paulette; Afkhami, Michelle; Pejovic, Tanja
• Other Names: Rasty Golnar Academic Editor.
• Is Part Of: Pathology research international. Volume 2012(2012)
• Publication Date: 2012-12-25
• Subjects: Pathology -- Periodicals; 571.905
• DOI: 10.1155/2012/960327
• Languages: English
• ISSNs: 2090-8091

Abstract

Abstract : The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.